|
|
| (5 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| {| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; | | __NOTOC__ |
| ! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Moexipril|{{fontcolor|#6C7B8B|Moexipril}}]]'''''
| | {{CMG}}; {{AE}} {{AZ}}, {{AM}} |
| |-
| | |
| ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | UNIVASC<sup>®</sup> FDA Package Insert
| | ===''Moexipril''=== |
| |-
| | |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Moexipril indications and usage|Indications and Usage]]
| | * [[Moexipril tablet]] |
| |-
| | |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Moexipril dosage and administration|Dosage and Administration]]
| | ===''Moexipril and Hydrochlorothiazide tablet''=== |
| |-
| | |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Moexipril contraindications|Contraindications]]
| | * [[Moexipril and Hydrochlorothiazide tablet]] |
| |-
| | |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Moexipril warnings and precautions|Warnings and Precautions]]
| | ==Overview== |
| |-
| | |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Moexipril adverse reactions|Adverse Reactions]]
| | '''Moexipril''' tablet is an angiontensin converting enzyme inhibitor drug that is FDA approved for the treatment of [[hypertension]], [[heart failure]], left ventricular dysfunction after [[myocardial infarction]], [[diabetic nephropathy]]. Adverse reactions include hypotension, rash, hyperkalemia, disorder of taste, cough. [[hypotension]], [[rash]], [[hyperkalemia]], disorder of taste, [[cough]]. |
| |-
| | |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Moexipril drug interactions|Drug Interactions]]
| | ==Category== |
| |-
| | |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Moexipril use in specific populations|Use in Specific Populations]]
| | Antihypertensive Agents, Angiotensin Converting Enzyme Inhibitors. |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Moexipril overdosage|Overdosage]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Moexipril description|Description]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Moexipril clinical pharmacology|Clinical Pharmacology]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Moexipril clinical studies|Clinical Studies]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Moexipril how supplied storage and handling|How Supplied/Storage and Handling]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Moexipril patient counseling information|Patient Counseling Information]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Moexipril labels and packages|Labels and Packages]]
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Clinical Trials on Moexipril
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} ClinicalTrials.gov]
| |
| |-
| |
| |}
| |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2], Amr Marawan, M.D. [3]
Moexipril
Moexipril and Hydrochlorothiazide tablet
Overview
Moexipril tablet is an angiontensin converting enzyme inhibitor drug that is FDA approved for the treatment of hypertension, heart failure, left ventricular dysfunction after myocardial infarction, diabetic nephropathy. Adverse reactions include hypotension, rash, hyperkalemia, disorder of taste, cough. hypotension, rash, hyperkalemia, disorder of taste, cough.
Category
Antihypertensive Agents, Angiotensin Converting Enzyme Inhibitors.